Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)

BACKGROUND: Homologous recombination deficiency (HRD)-causing alterations have been reported in triple-negative breast cancer (TNBC). We hypothesized that TNBCs with HRD alterations might be more sensitive to anthracycline plus cyclophosphamide-based chemotherapy and report on HRD status and BRCA1 p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Oncol
Main Authors: Sharma, P, Barlow, W E, Godwin, A K, Pathak, H, Isakova, K, Williams, D, Timms, K M, Hartman, A R, Wenstrup, R J, Linden, H M, Tripathy, D, Hortobagyi, G N, Hayes, D F
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5888953/
https://ncbi.nlm.nih.gov/pubmed/29293876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx821
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados